BMS 309403

Key Product Details

Product Description

BMS 309403 is a potent and selective fatty acid binding protein 4, adipocyte (FABP4) inhibitor (K_i values are <2, 250 and 350 nM for FABP4, FABP3 and FABP5 respectively). Decreases fatty acid uptake in adipocytes in vitro and reduces atherosclerotic lesion area in a mouse model of atherosclerosis. Reduces blood glucose levels and increases insulin sensitivity in a mouse model of obesity. Orally active.

Product Specifications for BMS 309403

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for BMS 309403

The following data is based on the product molecular weight 474.55.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.11 mL	10.54 mL	21.07 mL
5 mM	0.42 mL	2.11 mL	4.21 mL
10 mM	0.21 mL	1.05 mL	2.11 mL
50 mM	0.04 mL	0.21 mL	0.42 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 13 publications citing the usage of this product.

• Sulsky Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP). Bioorg.Med.Chem.Lett. 2007 PMID: 17502136
• Lin BMS309403 stimulates glucose uptake in myotubes through activation of AMP-activated protein kinase. PLoS ONE 2012 PMID: 22952994
• Furuhashi Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007 PMID: 17554340

Product Documents for BMS 309403